Abstract
Background:
Weight gain and associated medical morbidity offset the reduction of extrapyramidal side effects associated with atypical antipsychotics. Efforts to control weight in antipsychotic-treated patients have yielded limited success.
Methods:
We studied the impact of an intensive 24-week program of diet, exercise, and counseling in 17 chronically psychotic patients (10 women, seven men) who entered at high average body weight (105.0±18.4 kg) and body mass index (BMI) (36.6±4.6 kg/m2). A total of 12 subjects who completed the initial 24 weeks elected to participate in an additional 24-week, less intensive extension phase.
Results:
By 24 weeks, weight-loss/patient averaged 6.0 kg (5.7%) and BMI decreased to 34.5 (by 5.7%). Blood pressure decreased from 130/83 to 116/74 (11% improvement), pulse fell slightly, and serum cholesterol and triglyceride concentrations changed nonsignificantly. With less intensive management for another 24 weeks, subjects regained minimal weight (0.43 kg).
Conclusions:
These findings add to the emerging view that weight gain is a major health problem associated with modern antipsychotic drugs and that labor-intensive weight-control efforts in patients requiring antipsychotic treatment yield clinically promising benefits. Improved treatments without weight-gain risk are needed.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Allison D, Mentore J, Moonseong H, Chandler L, Cappelleri J, Infante M et al. Antipsychotic-induced weight-gain: a comprehensive research synthesis. Am J Psychiatr 1999; 156: 1686–1696.
Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J et al. Novel antipsychotics: comparison of weight-gain liabilities. J Clin Psychiatr 1999; 60: 358–363.
Basson BR, Kinon BJ, Taylor CC, Szymanski KA, Gilmore JA, Tollefson GD . Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatr 2001; 62: 231–238.
Kinon BJ, Basson BR, Gilmore JA, Tollefson GD . Long-term olanzapine treatment: weight change and weight related factors in schizophrenia. J Clin Psychiatr 2001; 62: 92–100.
Wetterling T . Body weight-gain with atypical antipsychotics: comparative review. Drug Safety 2001; 24: 59–73.
Vanina Y, Podolskaya A, Sedky K, Shahab H, Siddiqui A, Munshi F et al. Body weight changes associated with psychopharmacology. Psychiatr Serv 2002; 53: 842–847.
Zimmermann U, Kraus T, Himmerich H, Schuld A, Pollmacher T . Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. J Psychiatr Res 2003; 37: 193–220.
Tecott LH, Sun LM, Akana SF, Strack AM, Lowenstein DH, Dallman MF et al. Eating disorder and epilepsy in mice lacking 5 HT2C serotonin receptors. Nature 1995; 374: 541–546.
Leibowitz SF, Alexander JT . Hypothalamic serotonin in control of eating behavior, meal size, and body weight. Biol Psychiatr 1998; 44: 851–864.
McIntyre RS, Mancini DA, Basile VS . Mechanisms of antipsychotic-induced weight gain. J Clin Psychiatr 2001; 62 (Suppl 23): 23–29.
Reynolds G, Zhang ZJ, Zhang XB . Association of antipsychotic drug-induced weight-gain with a 5-HT2C receptor gene polymorphism. Lancet 2002; 359: 2086–2087.
Takahashi K, Suwa H, Ishikawa T, Kotani H . Targeted disruption of H3 receptors results in changes in brain histamine tone leading to an obese phenotype. J Clin Invest 2002; 110: 1791–1799.
Aronne LJ . Epidemiology, morbidity, and treatment of overweight and obesity. J Clin Psychiatr 2001; 62 (Suppl 23): 13–22.
Haupt DW, Newcomer JW . Abnormalities in glucose regulation associated with mental illness and treatment. J Psychosom Res 2002; 53: 925–933.
Henderson DC, Ettinger ER . Schizophrenia and diabetes. Int Rev Neurobiol 2002; 51: 481–501.
Kannel WB, Wilson PW, Nam BH, D’Agostino RB . Risk stratification of obesity as a coronary risk factor. Am J Cardiol 2002; 90: 697–701.
Green AI, Canuso CM, Brenner MJ, Wojcik JD . Detection and management of comorbidity in patients with schizophrenia. Psychiatr Clin North Am 2003; 26: 115–139.
Sharma R, Markar HR . Mortality in affective disorder. J Affect Disord 1994; 31: 91–96.
Angst F, Stassen HH, Clayton PJ, Angst J . Mortality of patients with mood disorders: follow-up over 34–38 years. J Affect Disord 2002; 68: 167–181.
Rosh A, Sampson BA, Hirsch CS . Schizophrenia as a cause of death. J Forensic Sci 2003; 48: 164–167.
Kane JM, Casey DE, Daniel DG, Newcomber JW . Antipsychotic agents: minimizing side effects to maximize compliance. J Clin Psychiatr 1996; 57 (Suppl 10): 1–12.
Baldessarini RJ, Tondo L, Viguera AC . Effects of discontinuing lithium maintenance treatment. Bipolar Disord 1999; 1: 17–24.
Weiden PJ, Mackell JA, McDonnell DD . Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res 2004; 66: 51–57.
Richardson CR, Faulkner G, McDevitt J, Skrinar GS, Hutchinson DS, Piette JD . Integrating physical activity into mental health services for persons with serious mental illness. Psychiatr Serv 2005; 56: 324–331.
Faulkner G, Soundy AA, Lloyd K . Schizophrenia and weight management: a systematic review of interventions to control weight. Acta Psychiatr Scand 2003; 108: 324–332.
Aquila R, Emanuel M . Interventions for weight gain in adults treated with novel antipsychotics. Prim Care Comp J Clin Psychiatr 2000; 2: 20–23.
Menza M, Vreeland B, Minsky S, Gara M, Radler DR, Sakowitz M . Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program. J Clin Psychiatr 2004; 65: 471–477.
Pendlebury J, Haddad P, Dursun S . Evaluation of a behavioural weight management programme for patients with severe mental illness: 3 year results. Hum Psychopharmacol 2005; 20: 447–448.
Wilmore J, Costill D . Physiology of Sport and Exercise. Human Kinetics Publishers: Champagne, IL, 1994.
Guy W (ed). Clinical global impressions. ECDEU Assessment Manual for Psychopharmacology US Dept. Health, Education and Welfare publication (ADM) 76–338. National Institute of Mental Health: Rockville, MD, 1976. pp 218–222.
Overall JE, Gorham DR . The brief psychiatric rating scale. Psychol Rep 1962; 10: 799–812.
Ferguson RJ, Robinson AB, Splaine M . Use of the reliable change index to evaluate clinical significance in SF-36 outcomes. Qual Life Res 2002; 11: 509–516.
Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K . The UKU side effect rating scale: new comprehensive rating scale for psychotropic drugs and cross-sectional study of side effects in neuroleptic patients. Acta Psychiatr Scand Suppl 1987; 334: 1–100.
Simpson GM, Angus JWS . A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212: 11–19.
Barnes TR . A rating scale for drug-induced akathisia. Br J Psychiatr 1989; 154: 672–676.
Psychopharmacology Research Branch, National Institute of Mental Health. Abnormal involuntary movement scale (AIMS). In: Guy W (ed). ECDEU Assessment Manual for Psychopharmacology, Revised. US Dept Health, Education, and Welfare publication (ADM) 76–338. National Institute of Mental Health: Rockville, MD, 1976. pp 534–537.
Heinrichs DW, Hanlon TE, Carpenter Jr WT . The quality of life scale: instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bull 1984; 10: 388–398.
Kopelman PG . Obesity as a medical problem. Nature 2000; 404: 6435–6439.
Heshka S, Anderson JW, Atkinson RL, Greenway FL, Hill JO, Phinney SD et al. Weight-loss with self-help compared with a structured commercial program: randomized trial. JAMA 2003; 289: 1792–1798.
Bravata DM, Sanders L, Huang J, Krumholz HM, Olkin I, Gardner CD et al. Efficacy and safety of low-carbohydrate diets: systematic review. JAMA 2003; 289: 1837–1850.
Schuler-springorum M, Hebebrand J, Wehmeier PM, Remschmidt R . Is topiramide effective for weight-loss in neuroleptic-indeuced obesity? Z Kinder Jugendpsychiatr Psychother 2002; 30: 521–558.
Gadda KM, Franciscy DM, Wagner HR, Krishnan KR . Zonisamide for weight loss in obese adults: randomized controlled trial. JAMA 2003; 239: 1820–1825.
Baldessarini RJ, Tarazi FI . Drugs and the treatment of psychiatric disorders: Antipsychotic and antimanic agents. In: Hardman JG, Limbird LE, Gilman AG (eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics, Chapter 20, 10th edn. McGraw-Hill Press: New York, 2001. pp 485–520.
Leucht S, Wahlbeck K, Hamann J, Kissling W . New generation antipsychotics vs low-potency conventional antipsychotics: A systematic review and meta-analysis. Lancet 2003; 361: 1581–1589.
Acknowledgements
This work is supported in part by grants from Eli Lilly Corporation (to FC), the Bruce J Anderson Foundation and the McLean Private Donors Neuropsychopharmacology Research Fund (to RJB).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Centorrino, F., Wurtman, J., Duca, K. et al. Weight loss in overweight patients maintained on atypical antipsychotic agents. Int J Obes 30, 1011–1016 (2006). https://doi.org/10.1038/sj.ijo.0803222
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.ijo.0803222
Keywords
This article is cited by
-
Amélioration de la santé cardiovasculaire par l’exercice physique chez les individus atteints de schizophrénie : un guide de pratique
Obésité (2015)
-
The Effectiveness of Lifestyle Interventions to Reduce Cardiovascular Risk in Patients with Severe Mental Disorders: Meta-Analysis of Intervention Studies
Community Mental Health Journal (2014)
-
Primary care-based educational interventions to decrease risk factors for metabolic syndrome for adults with major psychotic and/or affective disorders: a systematic review
Systematic Reviews (2013)
-
Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits
BMC Medicine (2012)
-
Changes in body weight, body composition and cardiovascular risk factors after long-term nutritional intervention in patients with severe mental illness: an observational study
BMC Psychiatry (2011)